Cipher Pharma has a huge upside, says Echelon Wealth

Mar 21 20:03 2019 Print This Article

Look for Cipher Pharmaceuticals (Cipher Pharmaceuticals Stock Quote, Chart TSX:CPH) to break out of its slump in 2019, says Doug Loe of Echelon Wealth Partners. Loe gives a 12-month return of 257 per cent for the stock, saying the specialty pharma company’s pipeline prospects are encouraging. Cipher Pharmaceuticals released its fourth quarter and fiscal 2018 […]

The post Cipher Pharma has a huge upside, says Echelon Wealth appeared first on Cantech Letter.

Read More

About Article Author

Cantech Letter

Founded in 2008 by Nick Waddell, Cantech Letter is an online magazine focusing on Canadian technology. The site has grown into one of the most popular and respected financial sites in Canada, and was described by Canadian Business Magazine as “one of Canada’s premier technology newsletters”. Waddell, who is Senior Editor, is routinely called on by the mainstream media for perspective on Canadian technology, and has been featured on BNN, CTV News Channel, and the CBC program “The Lang and O’Leary Exchange” in addition to mainstream print media such as The Guardian, The International Business Times, The Globe and Mail, Macleans, The Waterloo Record , Canadian Business, Slate, and Business Insider. You can email Nick at nick@cantechletter.com Cantech Letter is focused on those companies listed on the TSX and TSXV Technology, Cleantech and Life Sciences Sectors. Each year we present the Cantech Letter Awards, which honor Canada’s Top Technology Stock and Top Technology Stock Executive.

Related Items

Week Ahead: Mild Pullbacks Likely; NIFTY Continues To Remain Vulnerable To Sell-offs At Higher Level

After having resisted to the resistance area of 11800-11840 for seven weeks, the markets loosened up a bit in the week that went by while ending with losses. NIFTY spent a previous couple of weeks in a defined range as it remained indecisive and did not make any convincing directional call. This we ...

Week Ahead: Mild Pullbacks Likely; NIFTY Continues To Remain Vulnerable To Sell-Offs At Higher Level

After meeting resistance around 11800-11840 for seven weeks, the markets loosened up a bit over the past week while ending with losses. NIFTY spent the previous couple of weeks in a defined range as it remained indecisive and did not make any convincing directional call. This week, the NIFTY witn ...

Medexus is Canada’s best specialty pharma stock, Mackie Research says

Following the company’s fourth quarter results, Mackie Research Capital analyst André Uddin is describing Medexus Pharmaceuticals (Medexus Pharmaceuticals News, Stock Quote, Chart TSX:MDP) as “extremely undervalued”. On Monday, MDP reported its Q4 and fiscal 2019 results. In the fourth quart ...

This Cannabis Stock is Higher than the Rest

Sorry, I could not resist the pun in that head line. Relative and absolute strength is often dependent on timeframe. One stock may show upside leadership on a one month timeframe, but be lagging on the three and six month timeframes. For example, Tilray (TLRY) is up 16.37% over the past month, but ...

First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants

Generic drugs perform better financially if they get to market first. The advantage is amplified if they get there more than one month ahead of competitors. The post First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants appeared first on DrugPatentWatch - Make B ...

Martello is benefiting from “the Bruce Linton effect”, PI says

Its stock having tripled since co-Chairman Bruce Linton parted ways with Canopy Growth Corp, Martello Technologies (Martello Technologies News, Stock Quote, Chart TSXV:MTLO) is now in a much better place to ramp up with some M&A, says PI Financial analyst David Kwan. Kawn today provided an intraday ...

Bellus Health gets new $4.10 price target at Mackie Research Capital

Recent shifts in the competitive landscape have Mackie Research Capital analyst André Uddin raising his price target on Bellus Health (Bellus Health News, Stock Quote, Chart TSX:BLU). Uddin says in the landscape of chronic cough treatments, P2X3 inhibitors are showing the most promise and advanced ...

Canopy Growth’s Bruce Linton say his exit was not entirely unexpected

His tenure at the helm of Canada’s biggest pot co may be over but Bruce Linton is still cheerleading for the emerging sector which for many years now had Linton as its primary spokesperson and key visionary. This week, news broke that Canopy Growth’s board of directors had asked Linton to step ...

Sernova Corporation has an upside of 317 per cent, Echelon says

Impressive interim outcome data from Sernova Corporation (Sernova Corporation News, Stock Quote, Chart TSXV:SVA) has Echelon Wealth Partners analyst Douglas Loe staying bullish on the regenerative medicine tech company. In a Wednesday update to clients, Loe reiterated his “Speculative Buy” rati ...

Time to hop on board Acasti Pharma, says Mackie Research

With its best-in-class omega-3 drug CaPre currently in Phase III trials, Acasti Pharma (Acasti Pharma News, Stock Quote, Chart TSXV:ACST) is ready for liftoff, says Mackie Research Capital Corporation analyst André Uddin. On Thursday, Uddin reiterated his “Speculative Buy” rating and $8.70 tar ...